Process optimization of large-scale production of recombinant adeno-associated vectors using dielectric spectroscopy

被引:0
|
作者
Alejandro Negrete
Geoffrey Esteban
Robert M. Kotin
机构
[1] US National Institutes of Health,Laboratory of Biochemical Genetics, National Heart, Lung, and Blood Institute
[2] FOGALE Nanotech,undefined
来源
关键词
Adeno-associated vectors; Gene therapy; Dielectric spectroscopy; Large-scale; Bioprocessing; Harvesting time;
D O I
暂无
中图分类号
学科分类号
摘要
A well-characterized manufacturing process for the large-scale production of recombinant adeno-associated vectors (rAAV) for gene therapy applications is required to meet current and future demands for pre-clinical and clinical studies and potential commercialization. Economic considerations argue in favor of suspension culture-based production. Currently, the only feasible method for large-scale rAAV production utilizes baculovirus expression vectors and insect cells in suspension cultures. To maximize yields and achieve reproducibility between batches, online monitoring of various metabolic and physical parameters is useful for characterizing early stages of baculovirus-infected insect cells. In this study, rAAVs were produced at 40-l scale yielding ~1 × 1015 particles. During the process, dielectric spectroscopy was performed by real time scanning in radio frequencies between 300 kHz and 10 MHz. The corresponding permittivity values were correlated with the rAAV production. Both infected and uninfected reached a maximum value; however, only infected cell cultures permittivity profile reached a second maximum value. This effect was correlated with the optimal harvest time for rAAV production. Analysis of rAAV indicated the harvesting time around 48 h post-infection (hpi), and 72 hpi produced similar quantities of biologically active rAAV. Thus, if operated continuously, the 24-h reduction in the production process of rAAV gives sufficient time for additional 18 runs a year corresponding to an extra production of ~2 × 1016 particles. As part of large-scale optimization studies, this new finding will facilitate the bioprocessing scale-up of rAAV and other bioproducts.
引用
收藏
页码:761 / 772
页数:11
相关论文
共 50 条
  • [31] Recombinant adeno-associated virus vectors for gene therapy
    Conlon, TJ
    Flotte, TR
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) : 1093 - 1101
  • [32] Intracellular transport of recombinant adeno-associated virus vectors
    M Nonnenmacher
    T Weber
    Gene Therapy, 2012, 19 : 649 - 658
  • [33] Recombinant adeno-associated viral vectors in the nervous system
    Burger, C
    Nash, K
    Mandel, RJ
    HUMAN GENE THERAPY, 2005, 16 (07) : 781 - 791
  • [34] Intracellular transport of recombinant adeno-associated virus vectors
    Nonnenmacher, M.
    Weber, T.
    GENE THERAPY, 2012, 19 (06) : 649 - 658
  • [35] Gene therapy: Recombinant adeno-associated virus vectors
    Smith-Arica J.R.
    Bartlett J.S.
    Current Cardiology Reports, 2001, 3 (1) : 43 - 49
  • [36] Production, Purification and Characterization of Adeno-Associated Vectors
    Ayuso, Eduard
    Mingozzi, Federico
    Bosch, Fatima
    CURRENT GENE THERAPY, 2010, 10 (06) : 423 - 436
  • [37] Production and characterization of adeno-associated viral vectors
    Grieger, Joshua C.
    Choi, Vivian W.
    Samulski, R. Jude
    NATURE PROTOCOLS, 2006, 1 (03) : 1412 - 1428
  • [38] Production and characterization of adeno-associated viral vectors
    Joshua C Grieger
    Vivian W Choi
    R Jude Samulski
    Nature Protocols, 2006, 1 : 1412 - 1428
  • [39] Process Development for Recombinant Adeno-Associated Virus Production Using a Design of Experiments Model
    Murthy, Vidya
    Magnusson, Ann-Christin
    MOLECULAR THERAPY, 2022, 30 (04) : 80 - 81
  • [40] Organoid transduction using recombinant adeno-associated viral vectors: Challenges and opportunities
    Belova, Lyubava
    Lavrov, Alexander
    Smirnikhina, Svetlana
    BIOESSAYS, 2022, 44 (09)